| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Bridgewater Associates · Ray Dalio | $243.9K | 0.00% | 7.04K | −83% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Lisa McClain MI09 | 1 | +$8.0K | Bought Aug 4, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Aug 4, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Sep 12, 25 (39d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | Okupe OluyemiChief Financial Officer | Sale at price 29.95 per share. | 29.3K | $876.85K |
| Sep 21, 2026 | Okupe OluyemiChief Financial Officer | Conversion of Exercise of derivative security at price 5.01 per share. | 14K | $70.14K |
| Sep 15, 2026 | Boughton SoleilOfficer | Sale at price 27.86 per share. | 6.2K | $173.74K |
| Sep 14, 2026 | Chi Michael YChief Operating Officer | Sale at price 28.39 per share. | 14K | $398.23K |
| Sep 14, 2026 | Elshenawy MohamedChief Technology Officer | Sale at price 28.39 per share. | 8K | $225.81K |
| Sep 1, 2026 | Boughton SoleilOfficer | Sale at price 28.33 per share. | 3.5K | $97.97K |
| Aug 24, 2026 | Dudum AndrewChief Executive Officer | Stock Gift at price 0.00 per share. | 463.3K | — |
| Aug 18, 2026 | Okupe OluyemiChief Financial Officer | Sale at price 29.99 per share. | 4.9K | $148.11K |
| Aug 18, 2026 | Okupe OluyemiChief Financial Officer | Conversion of Exercise of derivative security at price 5.01 per share. | 4.9K | $24.74K |
| Aug 18, 2026 | Boughton SoleilOfficer | Sale at price 27.55 per share. | 25.1K | $691.81K |
| Aug 17, 2026 | Autor Deborah MOfficer and Director | Sale at price 27.85 per share. | 16.8K | $467.13K |
| Aug 16, 2026 | Okupe OluyemiChief Financial Officer | Sale at price 27.89 - 35.09 per share. | 64.8K | $2.21M |
| Aug 16, 2026 | Okupe OluyemiChief Financial Officer | Conversion of Exercise of derivative security at price 5.01 per share. | 81K | $47.03K |
| Aug 13, 2026 | Wells David BDirector | — | 778 | — |
| Aug 13, 2026 | Payne Christopher DDirector | — | 545 | — |
| Aug 13, 2026 | Schultz KareDirector | — | 6.6K | — |
| Aug 13, 2026 | Chi Michael YChief Operating Officer | — | 86.3K | — |
| Aug 13, 2026 | Elshenawy MohamedChief Technology Officer | — | 188.3K | — |
| Aug 13, 2026 | Dudum AndrewChief Executive Officer | — | 155K | — |
| Aug 13, 2026 | Carroll Patrick HarrisonOfficer | — | 26.2K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.6 | -46.4 | 43.0 | 30.9 | -3.8 | 32.6 | -19.9 | 6.5 | 0.7 | 0.4 | −7.9% | ||
| 2025 | 54.2 | 20.9 | -34.5 | 12.0 | 70.9 | -11.9 | 32.8 | -36.0 | 33.9 | -19.9 | -12.5 | -18.3 | +34.3% |
| 2024 | -3.6 | 52.0 | 18.6 | -19.0 | 55.0 | 4.0 | 5.2 | -30.6 | 25.1 | 2.2 | 71.1 | -25.0 | +171.7% |
| 2023 | 29.2 | 36.1 | -12.0 | 16.8 | -22.9 | 5.1 | -4.6 | -25.2 | -6.3 | -4.9 | 48.7 | 0.1 | +38.8% |
| 2022 | -25.5 | 7.0 | 2.1 | -21.0 | -4.0 | 12.1 | 36.6 | 2.7 | -12.3 | -18.6 | 36.3 | 3.6 | −2.1% |
| 2021 | 30.1 | -23.3 | -9.2 | -6.4 | 16.4 | -24.4 | -27.4 | -0.4 | -4.3 | 3.4 | -16.0 | 0.0 | −55.1% |
| 2020 | 1.5 | -0.1 | -0.4 | -0.3 | -0.4 | 2.4 | 1.3 | 1.7 | 12.1 | -13.2 | 3.1 | 38.8 | +47.5% |
| 2019 | -0.4 | 0.9 | -0.2 | +0.3% |
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.
Buy / hold / sell counts